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Abstract 
Renalase is a recently identified flavoprotein oxidase, secreted mainly by the kidneys, which takes part in the degradation of catechol-
amines. The catecholamine inactivating effect results in the modulation of the sympathetic system tension and, consequently, in a decrease 
of blood pressure, myocardial contractility, heart rate, and vascular tone. Besides its enzymatic capacity, renalase shows cytoprotective 
properties by activating mitogen-activated protein kinase (MAPK) pathway. Several single nucleotide polymorphisms (SNPs) of the 
renalase gene have been identified, of which the most widely studied in relation to the development of selected diseases are rs2296545, 
rs10887800, and rs2576178. Numerous publications prove the contribution of renalase to the occurrence of cardiovascular diseases, 
kidney diseases, ischaemic stroke, diabetes type 1 and 2, as well as female infertility and schizophrenia. Further extended research into 
the various mechanisms of renalase activity may result in the use of this oxidase or its analogues as a therapeutic and/or diagnostic tool. 
(Endokrynol Pol 2020; 71 (4): 334–342)
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Introduction 
Renalase is a flavoprotein oxidase whose major sources 
are renal proximal tubules. To a lesser degree, it is also 
expressed in the heart, skeletal muscles, endothelium, 
small intestine, adipose tissue, brain, liver, and re-
productive/steroidogenic system. Initially only four, 
and currently as many as seven isoforms of human 
renalase are described (h renalase 1–7). The main and 
only isoform that has so far been isolated from blood 
and urine is h-renalase-1. This molecule is composed 
of 342 amino acids, and its molecular weight reaches 
37.85 kDa [1–3]. Renalase has a similar amino acid 
identity as monoamine oxidase A (MAO-A) at a level 
of 13.2%. Both of these molecules inactivate catechol-
amines, although renalase is the only identified amine 
oxidase functioning extracellularly. The inactivation of 
catecholamines can be achieved due to the presence 
of cofactors flavin adenine dinucleotide (FAD) and 
nicotinamide adenine dinucleotide (NAD), and it oc-
curs with the greatest affinity for dopamine, followed 
by adrenaline and ultimately noradrenaline [1, 4, 5]. 
Firstly, secreted into the blood as an inactive form of 
prorenalase, it rapidly evolves into renalase, under the 
influence of excess catecholamines and the rise in blood 
pressure. The main function of activated renalase is to 
modulate blood pressure and heart rate by affecting 
fluctuations in catecholamine levels in peripheral blood 
[6, 7]. In recent years, a group of scientists represented 
by Baupre et al. published a study presenting an alter-
native metabolic pathway for renalase, in which it acts 
as an a-NAD(P)H oxidase/anomerase. The described 
reaction consists of a rapid reduction of the renalase 
flavin cofactor thanks to low NADH and NADH equi-
librium concentrations, followed by the reaction of the 
reduced cofactor with molecular oxygen. This reac-
tion produces hydrogen peroxide and nicotinamide 
dinucleotide in the b-form, and this entire process is 
at least two times faster than any reaction previously 
proposed with catechol neurotransmitters [8, 9]. Inde-
pendently of its enzymatic functions, renalase has the 
properties of cytokine, which, as a result of reacting 
with plasma membrane receptor PMCA4b, activates the 
mitogen-activated protein kinase (MAPK) pathway. The 
consequence of triggering this cascade is a cytoprotec-
tive, anti-inflammatory effect and protection from hy-
poxia and apoptosis [10, 11]. Different kinds of renalase 
activity make it necessary to search for its participation 
in the pathophysiology of diseases as well as potential 
therapeutic and diagnostic effects. 
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hypertension in the mechanism of hyperactivation 
of the sympathetic nervous system. Maciorkowska 
et al. conducted experimental studies on patients 
with primary hypertension, whose concentrations of 
renalase, vascular adhesion protein 1 (VAP-1), and 
catecholamines in serum were measured. The con-
centrations of renalase and VAP-1 were significantly 
higher in the study group compared to healthy indi-
viduals. Moreover, a correlation between renalase and 
norepinephrine concentrations was observed as well 
as a correlation between renalase concentrations and 
both systolic and diastolic ambulatory blood pressure 
measurements [22]. Opposite results were obtained by 
Wybraniec et al., who, from 50 patients after surgical 
aortic coarctation correction and 50 healthy patients, 
selected those with arterial hypertension for further 
investigation. In both groups renalase concentrations 
were significantly lower among patients with hyper-
tension, but what distinguishes these studies from the 
others presented above is the fact that renalase was 
determined in plasma instead of serum [23]. Similar 
findings were presented by Schlaich et al., showing 
a decreased concentration of plasma renalase among 
patients with resistant hypertension compared to 
healthy individuals. The difference between these stud-
ies and the others is the method for determining the 
concentration of the renalase — western blot technique 
instead of enzyme-like immunosorbent assay (ELISA) 
[24]. In spite of experimental studies determining the 
levels of renalase in serum or plasma of peripheral 
blood plasma in patients with hypertension, genetic 
Renalase gene polymorphism 
Nowadays, genome-wide association studies (GWAS) 
have become a well-established method in the explora-
tion of polymorphisms of particular genes contributing 
to the development of many complex diseases. The 
human renalase gene (RNLS) is located on chromo-
some 10q23.33 and consists of ~310 Kbp with 10 exons 
[12]. Genetic analysis revealed many single nucleotide 
polymorphisms (SNPs) of the renalase gene associated 
with a wide range of diseases. The greatest amount 
of evidence is mainly based on the SNPs rs2296545, 
rs10887800, and rs2576178 connected with different 
cardiovascular disorders, kidney diseases, diabetes type 
1 and 2, ischaemic stroke, and others (Tab. 1) [10, 12]. 
Coronary artery disease
Understanding the renalase impact on oscillations of 
catecholamine levels explains its role in the regulation 
of blood pressure, myocardial contraction, heart rate, 
and vascular tone [14]. Coronary artery disease is first 
among cardiovascular diseases in terms of occurrence 
and mortality. The aetiology of these illnesses is multi-
factorial, including congenital predispositions, lifestyle, 
and environmental factors. The correlation between 
renalase and the prevalence of coronary artery disease 
(CAD) is widely described. He et al. conducted a study 
on CAD patients divided into groups according to the 
number of occupied coronary artery branches. Not 
only were significantly increased levels of renalase in 
the control group revealed, but also dependencies of 
the renalase concentration on the severity of the disease 
[15]. The relationship between the polymorphism of the 
renalase gene (rs2576178 and rs10887800) and the oc-
currence of CAD has been demonstrated several times 
[16]. The research performed by Li et al. compared 
renalase SNPs among patients with hypertension and 
accompanying CAD versus patients with hypertension 
only [17]. Also, Stec et al. confirmed the connection 
between the renalase gene and CAD by performing 
a study of patients on haemodialysis [18]. 
Primary hypertension
Primary hypertension is a complex disease, and the 
literature describes many mechanisms that may con-
tribute to the development of this disease or intensify 
its course. The factors involved in the pathophysiology 
of hypertension development include increased salt 
intake, abnormal regulation of the renin–angioten-
sin–aldosterone system (RAAS), and hyperactivation 
of the sympathetic system [19–21]. The low level of 
renalase can contribute to the development of primary 
Table 1. The most studied single nucleotide polymorphisms 
(SNPs) of renalase gene related with elevated risk of selected 
diseases
Single nucleotide 




























rs10509540 Diabetes type 1 [44]
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relationships between renalase and essential hyperten-
sion have been determined. Zhao et al. presented the 
association between single nucleotide polymorphisms 
in the renalase gene (rs2296545 and rs2576178) and the 
occurrence of essential hypertension among the Han 
Chinese population [25]. It seems to be certain that re-
nalase and hypertension are related, but it is not clear 
whether abnormal renalase concentration is a factor 
predisposing to hypertension or is its result.
Hypertension during pregnancy
Hypertension also affects the group of pregnant 
women and constitutes 2–8% of all pregnancy complica-
tions. Several studies proved the connection between 
the polymorphism of the renalase genes (rs 10887800 
and rs2576178) and the occurrence of elevated pressure 
in the course of pre-eclampsia (PE) and pregnancy-in-
duced hypertension (PIH). Elsethoy et al. submitted 
a study of women suffering from PIH, which revealed 
that the distribution of both genotypes mentioned 
above was significantly higher in the study group 
comparing to the controls. The research also presents 
graduating values of systolic and diastolic blood pres-
sures according to the genotype dominance [26]. Similar 
studies carried out by Bagci et al. concerned a group 
women with PE, not only showing the polymorphism 
of the rs108878800 renalase gene, but also confirming 
a significant statistical differentiation of systolic and 
diastolic pressure depending on the genotype [27]. 
Teimoori et al. demonstrated opposite results by study-
ing SNPs of a renalase gene in women with PE. They 
showed that the combination of rs10887800 GG and 
rs2576178 GG genotypes significantly increased the 
risk of pre-eclampsia, although the polymorphisms 
themselves were not significantly more frequent in the 
study group than in the controls [28]. Serum renalase 
determinations in pre-eclampsia, hypertension, and 
healthy pregnant women were performed by Jamil et 
al. without significant differences in renalase concen-
trations between these three groups [29]. However, 
two independent scientific groups represented by 
Niadany et al. and Yilmas et al. presented significantly 
lower renalase concentrations in PE women compared 
to healthy pregnant women [30, 31]. In conclusion, it 
has been repeatedly proven that the polymorphism of 
the renalase gene is associated with the occurrence of 
hypertensive conditions in pregnant women and can be 
considered as a genetic risk factor of these conditions.
Chronic kidney disease
The links between renalase and kidney diseases are 
widely described in the literature. Chronic kidney 
disease (CKD) is the most widely described kidney 
disorder associated with renalase levels in both adults 
and children. Several studies have proven that the 
concentrations of renalase in serum are significantly 
higher in patients with CKD than in the control group 
and elevated with the increasing stage of renal failure. 
A study among a group of patients undergoing hae-
modialysis was carried out by Zbroch et al., who docu-
mented significantly higher renalase concentrations in 
the study group than in healthy individuals. The level 
of renalase concentration was not related to arterial 
pressure, heart rate, time of haemodialysis, type of hy-
potensive treatment, or residual kidney function [32]. 
Slightly later, research involving patients undergoing 
peritoneal dialysis, besides the haemodialysis group, 
was presented. In addition to the renalase, dopamine 
and norepinephrine concentrations were also deter-
mined in all studied groups; however, no correlation 
between all these substances was proven. Among the 
patients undergoing haemodialysis, patients with con-
comitant coronary artery disease were identified and 
diagnosed with cardiac death. In this group renalase 
concentration was significantly higher than in other 
haemodialyzed patients, which is a hint to deepen 
the pathophysiology of renalase in patients with CKD 
and CAD [33]. Subsequent studies confirmed higher 
renalase concentrations among patients with CKD 
and a significant correlation between renalase levels 
and the renal injury markers creatinine and urea [34, 
35]. Similar results are presented in a study group that 
included children suffering from CKD [36]. Wiśniewska 
et al. presented corresponding conclusions concerning 
the group of patients with CKD, among whom serum 
renalase concentration was significantly higher than in 
the control group. Also, the measurement of renalase 
in erythrocytes was performed and showed a decrease 
in renalase and an increase in urea concentration in the 
control group [37]. All of these studies used the ELISA 
technique to determine plasma renalase concentration. 
Research involving western blot technique presented 
contrasting results, in which renalase concentrations 
were significantly lower in patients with CKD than in 
the controls. Despite the different techniques, a relation-
ship between the CKD stage and the renalase concen-
tration was also observed [1, 7]. The polymorphism of 
the renalase gene associated with kidney diseases was 
investigated in patients after allogeneic kidney trans-
plants; however, no significant connection with renal 
transplant function was established [38].
Ischaemic stroke
The fact that the expression of renalase also occurs in 
endothelium cells raises the suspicion that this enzyme 
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of renalase and catecholamines in the control group, 
it was demonstrated that the renalase/catecholamine 
ratio correlated strongly with the occurrence of insulin 
resistance [45]. 
Female infertility 
The growing number of infertile couples around the 
world, currently reaching 10–15%, is leading to the 
search for its causes in genetics [46]. The research per-
formed by Fatima et al. to discover a polymorphism of 
the renalase gene among infertile women included 508 
fertile and 164 women who were infertile due to various 
reasons. The study proved a significant correlation of 
SNPs rs2576178 and rs10887800 with female infertility 
of unknown cause and with infertility caused by poly-
cystic ovarian syndrome. Scientists have hypothesised 
that SNPs in the renalase gene may interfere with the 
hormonal hypothalamic-pituitary-associated ovarian 
axis by affecting the degradation of catecholamines 
and increasing the number of stress hormones [47]. The 
link between renalase and the reproductive system is 
supported by the fact that Zhou et al. proved that the 
gonads and adrenal cortex are a source of renalase and 
suggested that it may affect fertility [3].
Schizophrenia
Catak et al. worked on a new direction of research on 
renalase, performing an assessment of the concentra-
tion of renalase and catecholamines among patients 
with schizophrenia. The speculations that renalase 
may be involved in the development of schizophrenia 
are justified by the fact that dopamine is involved in 
its pathogenesis. The study group showed statistically 
significantly lower renalase concentration and higher 
dopamine concentration compared to the controls [48]. 
Also, Hennebry et al. proved the presence of renalase 
in the peripheral nerves, hypothalamus, and pituitary 
gland and suggested that it could be involved in regula-
tion of neurotransmitter levels in the brain [2]. On the 
basis of these results, there is a suspicion that renalase 
may be involved in the development of many psychi-
atric and neurological diseases, which requires further 
investigation.
Renalase in children
Publications concerning the determination of renalase 
concentrations in children are relatively limited so far. 
The majority of studies regarding adolescents involve 
nephrological patients; however, until now no renalase 
determinations have been performed in neonates. Two 
studies conducted by the group of Skrzypczyk et al. 
may be involved in the pathogenesis of diseases that 
are caused by endothelial dysfunction [39]. This broad 
disease spectrum includes disorders associated with 
atherosclerotic plaque formation such as an ischaemic 
stroke. The association of the rs10887800 gene polymor-
phism with ischaemic stroke was reported in several 
studies. Firstly, Buraczyńska et al. performed tests on 
type 2 diabetes patients and proved the presence of 
SNP rs108887800 in the renalase gene in hypertensive 
patients with stroke. This finding was extended by 
examining a separate cohort of stroke patients free 
of diabetes. The association of the renalase gene with 
an increased risk of ischaemic stroke was confirmed 
in patients with and without type 2 diabetes [40]. In 
a study conducted by Li et al. a cohort of 212 ischaemic 
stroke patients and 244 controls were divided into 
groups according to the stage of stenosis of intracranial 
cerebral atherosclerotic vascular stenosis. The severity 
of the disease was assessed by imaging exams. It was 
shown that rs10887800 is connected with intracranial 
cerebral atherosclerotic vascular stenosis in ischaemic 
stroke patients [41]. At a similar time, Zhang et al. 
published their research in which they drew similar 
conclusions. In their study, 503 patients with ischaemic 
stroke were divided into groups due to complications 
and accompanying diseases such as hypertension and 
diabetes. A strong correlation between both rs10887800 
and rs2576178 SNPs and ischaemic stroke was demon-
strated in both hypertensive and non-hypertensive 
patients [42]. The connection between renalase and 
ischaemic stroke was also raised in the pilot study 
performed by Malyszko et al. on a group of haemodia-
lyzed patients. The serum renalase concentration was 
significantly lower in patients with a history of stroke. 
All the above studies show a link between renalase and 
ischaemic stroke, but the aetiology of this phenomenon 
is still unexplained [43].
Diabetes type 1 and 2
The risk of developing type 1 diabetes increases with 
the presence of common genetic loci. This knowledge 
has established the autoimmune basis of the disease. 
Genome-wide association studies present approxi-
mately 42 loci that affect the risk of type 1 diabetes and 
70 regions with suggestive evidence. Among this group, 
there is a region rs10509540 located in the renalase gene, 
which makes it possible to link type 1 diabetes and re-
nalase, but this mechanism needs further investigation 
[44]. The relationship between renalase and type 2 dia-
betes mellitus (T2DM) was studied by Wang et al., who 
performed serum renalase and catecholamine assays in 
75 T2DM patients and 13 healthy individuals. Further-
more, in addition to significantly higher concentrations 
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include children with glomerular kidney diseases (2017) 
and with chronic kidney diseases (2019). Although there 
was no significant difference between the renalase con-
centration in glomerulopathy patients and the control 
group, a correlation of renalase with daily proteinuria 
as well as with age, systolic and diastolic central blood 
pressure, eGFR, cholesterol, triglycerides, and pulse 
wave velocity was found. In a study on CKD patients, 
the results of renalase determinations were similar to 
those of most studies in the adult population. In the 
study group a higher concentration of renalase was 
found than in healthy individuals. Furthermore, a cor-
relation between renalase and CKD stage and negative 
correlation with eGFR were observed. The authors 
observed significantly decreasing renalase concentra-
tions with age among healthy patients, whereas there 
is no correlation between renalase and age in the study 
group [36, 49]. Taranta-Janusz et al. performed studies 
on paediatric patients with solitary functioning kid-
ney and discovered lower serum and urine renalase 
concentrations in patients in the study group [50]. The 
study conducted among teenage hypertensive patients 
presented by Lemiesz et al. showed significantly higher 
renalase concentrations among the study group com-
pared to healthy individuals. Furthermore, a significant 
correlation was found between the levels of renalase 
and uric acid and between renalase levels and mea-
surements of systolic and diastolic blood pressure [51]. 
Rybi-Szumińska et al. conducted a study to establish 
urine renalase reference values in the paediatric popula-
tion. Patients were divided into age groups in three-year 
intervals, which allowed them to observe a significantly 
higher renalase/creatinine ratio among patients less 
than three years old compared to older groups [52]. 
The fluctuation of renalase concentrations in the child 
population requires further evaluation. The number of 
studies among children is negligible; moreover, most of 
them are limited due to the small number of samples 
and low diversity among the study groups. 
Animal models
Until now, many studies prosecuting animal ex-
periments confirmed that the application of renalase 
triggers the decrease of blood pressure, myocardial 
contractility, and heart rate via regulating plasma cat-
echolamine levels [1, 53, 54]. Renalase knockout mice 
developed hypertension and have more severe renal 
and cardiac ischaemia. Moreover, administrating re-
combinant renalase in wild-type mice limits ischaemic 
kidney injury by decreasing renal tubular necrosis, 
apoptosis, and inflammation [55, 56]. Cytoprotective 
properties of renalase have been demonstrated during 
an experiment with rats after subtotal (5/6) nephrec-
tomy. Systemic delivery of renalase in the trial group 
prevented kidney injury and cardiac remodelling [14]. 
The impact of salt-intake on renalase expression in kid-
neys was confirmed by two independent experiments 
using Dahl salt-sensitive rats and Sprague-Dawley 
rats. Both investigations report that high salt intake 
inhibits the renal secretion of renalase. The influence of 
the renin-angiotensin-aldosterone system was excluded 
in this phenomenon [57, 58]. An impact on perfusion of 
kidneys was validated in an animal model of rats pre-
sented by Gu et al., with unilateral renal artery stenosis 
and other groups with infarction-induced heart failure. 
In both groups diminished renal blood flow led to the 
reduced renal expression of renalase [59].
Summary
Knowledge about the function and properties of re-
nalase as an enzyme and as a cytokine is constantly 
expanding. More and more organs and tissues in which 
renalase is produced or secreted into peripheral blood 
are being discovered. The association of renalase with 
various pathologies has been proven repeatedly and 
may provide a background for understanding the 
pathomechanism of its functioning. Determination of 
renalase concentration in the course of various chronic 
diseases has been evaluated in numerous studies 
(Tab. 2). Apart from learning the genetic connection of 
the renalase gene with diverse diseases and its influence 
on the course of these disorders, its therapeutic poten-
tial was also investigated. So far, numerous tests have 
been carried out on animal models using recombinant 
renalase. Due to the discovered properties of renalase 
based on catecholamine degradation and cytoprotec-
tive effects, it seems that therapeutic or diagnostic use 
of renalase may be valuable especially in states related 
to increased activity of the sympathetic system.  
Further work should also be focused on better stan-
dardisation of the method for determining renalase 
concentration. Variations in the usage of different 
measurement methods are an important part of the 
scientific discussion on the interpretation of renalase 
concentration in peripheral blood serum. Increased 
renalase concentrations in ELISA tests may result from 
cross-reaction detection of nonbiologically inactive 
enzyme fragments accumulating in advanced kidney 
disease. On the other hand, it is worth mentioning that 
western blot studies also need to be refined, because 
they used measurement of MAO activity and extrapo-
lated to renalase activity, while the similarity of the two 
substances is low [60, 61].
In conclusion, renalase plays a major role in the 
regulation of cardiovascular and renal systems via 
metabolising catecholamines and adjustment of the 
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sympathetic nervous system. Understanding its signal-
ling properties, independent of the enzymatic function, 
is an important step towards explaining the background 
of its cytoprotective and anti-inflammatory activity. 
The usage of recombinant renalase or its analogues is 
considered as a new possible therapeutic option.
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